ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome - Université de Lorraine Access content directly
Journal Articles Blood Year : 2022

ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome

Dates and versions

hal-03950370 , version 1 (21-01-2023)

Identifiers

Cite

Camilla Lemvigh, Erin Michelle Parry, Stephanie Deng, Nathan Dangle, Neil Ruthen, et al.. ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome. Blood, 2022, 140 (Supplement 1), pp.1807-1808. ⟨10.1182/blood-2022-162550⟩. ⟨hal-03950370⟩
22 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More